Veto cell suppression mechanisms in the prevention of allograft rejection

APMIS

Volumn 106, Issue 3, 1998, Pages 345-353

  Jacobsen, Ida Marie ^a   Claesson, Mogens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Suppression; T cells; Transplantation; Veto cells

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PREDNISONE;

ALLOGRAFT; ALLOTYPE SUPPRESSION; ANIMAL CELL; ANTIGEN RECOGNITION; BLOOD TRANSFUSION; CELL TRANSPLANTATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; KIDNEY GRAFT; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; T LYMPHOCYTE ACTIVATION; TARGET CELL;

EID: 0031961336     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1998.tb01356.x     Document Type: Review

References (53)

1. Amirayan, N. & Machy, P.: MHC class I molecules are implicated in costimulatory signals during TCR/CD3-induced activation. Cell. Immunol. 168: 1-12, 1996.
2. Anderson, C. B., Sicard, G. A. & Etheredge, E. E.: Pretreatment of renal allograft recipients with azathioprine and donor-specific blood products. Surgery 92: 315-321, 1982.
3. Anderson, C. B., Tyler, J. D., Rodey, G. E., Etheredge, E. E., Anderman, C. K., Flye, M. W., Jendrisak, M. D. & Sicard, G. A.: Preoperative immunomodulation of renal allograft recipients by concomitant immunosuppression and donor-specific transfusions. Transplant. Proc. 19: 1494-1497, 1987.
4. Anderson, C. B., Brennan, D., Keller, C., Goss, J., Shenoy, S., Burton, K., Sicard, G. & Flye, M. W.: Beneficial effects of donor-specific transfusions on long-term renal allograft function. Transplant. Proc. 27: 991-994, 1995.
5. Barber, W. H., Mankin, A., Laskow, D. A., Deierhoi, M. H., Julian, B. A., Curtis, J. J. & Diethelm, A. G.: Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51: 70-75, 1991.
6. Brennan, D. C., Mohanakumar, T. & Flye, M. W.: Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: A review of efficacy and mechanisms. Am. J. Kidney Dis. 26: 701-715, 1995.
7. Burlingham, W. J., Grailer, A. P., Fechner, J. H., Kusaka, S., Trucco, M., Kocova, M., Belzer, F. O. & Sollinger, H. W.: Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 59: 1147-1155, 1995.
8. Burlingham, W. J.: Chimerism after organ transplantation: Is there any clinical significance? Clin. Transplant. 10: 110-117, 1996.
9. Claësson, M. H. & Röpke, C.: Antiself suppressive (veto) activity of responder cells in mixed lymphocyte cultures. Curr. Top. Microbiol. Immunol. 126: 213-223, 1986.
10. Claësson, M. H.: Veto celll H-2 antigens: Veto cell activity is restricted by determinants encoded by K, D, and I MHC regions. Cell. Immunol. 109: 360-370, 1987.
11. Claësson, M. H. & Röpke, C.: Thymic epithelial cells. I. Expression of strong suppressive (veto) activity in mouse thymic epithelial cell cultures. Scand. J. Immunol. 32: 595-600, 1990.
12. Fast, L. D.: Generation and characterization of IL-2-activated veto cells. J. Immunol. 149: 1510-1515, 1992.
13. Fink, P. J., Rammensee, H.-G., Benedetto, J. D., Staerz, U. D., Lefrancois, L. & Bevan, M. J.: Studies on the mechanism of suppression of primary cytotoxic responses by clones cytotoxic T lymphocytes. J. Immunol. 133: 1769-1774, 1984.
14. Fink, P. J., Rammensee, H.-G. & Bevan, M. J.: Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them. J. Immunol. 133: 1775-1781, 1984.
15. Fink, P. J., Shimonkevitz, R. P. & Bevan, M. J.: Veto cells. Annu. Rev. Immunol. 6: 115-137, 1988.
16. + cells. J. Immunol. 145: 1646-1652, 1990.
17. + T cells. J. Exp. Med. 172: 719-728, 1990.
18. Hiruma, K., Nakamura, H., Henkart, P. A. & Gress, R. E.: Clonal deletion of postthymic T cells: Veto cells kill precursor cytotoxic T lymphocytes. J. Exp. Med. 175: 863-868, 1992.
19. Hiruma, K. & Gress, R. E.: Cyclosporine A and peripheral tolerance: Inhibition of veto cell-mediated clonal deletion of postthymic precursor cytotoxic T lymphocytes. J. Immunol. 149: 1539-1547, 1992.
20. Ju, S.-T., Panka, D. J., Cui, H., Ettinger, R., El-Khatib, M., Sherr, D. H., Stanger, B. Z. & Marshak-Rothstein, A.: Fas (CD95)/FasL interactions required for programmed cell death after T cell activation. Nature 373: 444-448, 1995.
21. + T helper precursor cells that can recognize class II MHC on injected donor lymphoid cells. J. Immunol. 146: 1104-1112, 1991.
22. Mann, R. A., Jetzt, A. E., Singh, A. B., Singh, M. & Cao, M.: In vitro generation of soluble suppressor factor in murine chronic graft versus host (GVH) disease. J. Clin. Lab. Immunol. 30: 163-180, 1995.
23. Martin, D. R., Sheng-Tanner, X. & Miller, R. G.: Rapid and long-term changes to host cytotoxic T lymphocyte precursors reactive to donor antigens caused by intravenous injection of histoincompatible lymphocytes. Transplantation 54: 125-129, 1992.
24. Martin, P. J.: Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens. Potential role of a veto mechanism. Blood 88: 962-969, 1996.
25. Miller, R. G.: An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it. Nature 287: 544-546, 1980.
26. Miller, R. G.: How a specific antiself deletion mechanism can affect the generation of the specificity repertoire. In: Secarz, E. E. & Cunningham, A. J. (Eds.): Strategies of immune regulation. Academic Press, New York 1980, pp. 507-511.
27. Miller, R. G., Muraoka, S., Claësson, M. H., Reimann, J. & Benveniste, P.: The veto phenomenon in T-cell regulation. Ann. N.Y. Acad. Sci. 532: 170-176, 1988.
28. Miller, R. G., Martin, D. R., Teh, H.-S., Kiziroglu, F. & Sambhara, S.: Role of the veto phenomenon in vivo. Progress Immunol. 7: 861-867, 1989.
29. Newton, W. T. & Anderson, C. B.: Planned preimmunization of renal allograft recipients. Surgery 74: 430-436, 1973.
30. + donor cells function as veto cells in the maintenance of tolerance across a major histocompatibility complex disparity in mixed-lymphoid radiation chimeras. Transplant. Proc. 25: 331-333, 1993.
31. Pierce, G. E. & Watts, L. M.: Do donor cells function as veto cells in the induction and maintenance of tolerance across an MHC disparity in mixed-lymphoid radiation chimeras? Transplant. Proc. 55: 882-887, 1993.
32. Pourshadi, M., Fazio, S. R. & Gozzo, J. J.: Abrogation of secondary skin allograft rejection by veto-like cells in donor bone marrow. Transplantation 56: 385-390, 1993.
33. Qi, Y., Berg, R., Singleton, M. A., Debrick, J. E. & Staerz, U. D.: Hybrid antibody mediated veto of cytotoxic T lymphocyte responses. J. Exp. Med. 183: 1973-1980, 1996.
34. Rammensee, H.-G., Fink, P. J. & Bevan, M. J.: Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen. J. Immunol. 133: 2390-2397, 1984.
35. Rammensee, H.-G., Bevan, M. J. & Fink, P. J.: Antigen specific suppression of T-cell responses -the veto concept. Immunol. Today 6: 41-43, 1985.
36. Rammensee, H.-G., Fink, P. J. & Bevan, M. J.: The veto concept: An economic system for maintaining self-tolerance of cytotoxic T lymhocytes. Transplant. Proc. 17: 689-692, 1985.
37. + T lymphocytes. Eur. J. Immunol. 19: 643-648, 1989.
38. 3 domain of class I MHC. Science 252: 1424-1427, 1991.
39. + cells whose class I MHC can bind the peptide. J. Immunol. 152: 1103-1109, 1994.
40. Sykes, M., Szot, G. L., Swenson, K. A. & Pearson, D. A.: Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nature Med. 3: 783-787, 1997.
41. + cytotoxic T lymphocytes by free antigenic peptide: A self-veto mechanism? J. Exp. Med. 183: 879-889, 1996.
42. Takeda, Y., Yanagie, H. & Maki, T.: Cloned veto cells as immunoregulators. Transplant. Proc. 25: 2743-2744, 1993.
43. Thomas, J. M., Carver, F. M., Cunningham, P. R. G., Olson, L. C. & Thomas, F. T.: Kidney allograft tolerance in primates without chronic immunosuppression - the role of veto cells. Transplantation 51: 198-207, 1991.
44. Thomas, J. M., Verbanac, K. M., Carver, F. M., Kasten-Jolly, J., Haisch, C. E., Gross, U. & Smith, J. P.: Veto cells in transplantation tolerance. Clin. Transplant. 8: 195-203, 1994.
45. Tscherning, T. & Claësson, M. H.: Veto-like downregulation of T-helper cell reactivity in vivo by injection of semiallogeneic spleen cells. Immunol. Lett. 29: 223-226, 1991.
46. Tscherning, T. & Claësson, M. H.: Veto suppression: The peripheral way of T cell tolerization. Exp. Clin. Immunogenet. 10: 179-188, 1993.
47. Verbanac, K. M., Carver, F. M., Haisch, C. E. & Thomas, J. M.: A role for transforming growth factor-beta in the veto mechanism in transplant tolerance. Transplantation 57: 893-900, 1994.
48. Watanabe-Fukunaga, R., Brannan, C. L., Copeland, N. G., Jenkins, N. A. & Nagata, S.: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317, 1992.
49. Yamamoto, H., Hirayama, M., Genyea, C. & Kaplan, J.: TGF-β mediates natural suppressor activity of IL-2-activated lymphocytes. J. Immunol. 152: 3842-3847, 1994.
50. Yanagie, H., Takeda, Y. & Maki, T.: In vitro and in vivo activities of long-term cultured veto suppressor clones. Transplant. Proc. 25: 350-351, 1993.
51. + antigen-specific T cells after in vivo exposure to male antigen. J. Immunol. 148: 3740-3745, 1992.
52. Skov, S., Bregenholt, S. & Claesson, M. H.: MHC class I ligation of T-cells activates the ZAP70 kinase, leads to an alternative phosphorylation of the TCR/CD3 zeta-chain and induces apoptosis. J. Immunol. 158: 3189, 1997.
53. 2-terminal kinase activity: A novel apoptotic pathway distinct from Fas-induced apoptosis. J. Cell Biol. 139: 1523, 1997.